Clinical practice guidelines for uterine corpus cancer: an update to the Korean Society of Gynecologic Oncology guidelines
- Author:
Woo Yeon HWANG
1
;
Ju-Hyun KIM
;
Joseph J. NOH
;
Min-Hyun BAEK
;
Min Chul CHOI
;
Yong Jae LEE
;
Maria LEE
;
Dong Hoon SUH
;
Yong Beom KIM
;
Dae-Yeon KIM
Author Information
- Publication Type:Practice Guideline
- From:Journal of Gynecologic Oncology 2025;36(1):e71-
- CountryRepublic of Korea
- Language:English
- Abstract: The Korean Society of Gynecologic Oncology has updated its clinical practice guidelines for endometrial cancer to incorporate advancements in recent high-quality randomized controlled trials. These guidelines address evolving treatment paradigms, and are tailored to the Korean medical context. Key updates include a strong recommendation for doxorubicin/trabectedin combination therapy in metastatic or recurrent unresectable leiomyosarcoma based on the significant survival benefits demonstrated in a randomized controlled trial. For advanced or recurrent endometrial cancer, immune checkpoint inhibitors combined with chemotherapy have received strong recommendations, owing to their proven efficacy and increased accessibility in Korea. Conditional recommendations were made for combination therapies involving durvalumab and olaparib, reflecting their potential benefits, but acknowledging regulatory and accessibility constraints. These guidelines aim to provide evidence-based, practical strategies to optimize care for patients with endometrial cancer while addressing unmet clinical needs and adapting global advancements to Korea’s healthcare environment.
